MedTrace Logo

Effect of Patient Demographics, Comorbidities, and Medications on Severity of NASH Fibrosis

NCT05357352 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 263

Last updated 2026-03-23

No results posted yet for this study

Summary

Few studies have evaluated an extensive list of possible risk factors for NAFLD for their association with presence and severity of histologic features. We wish to conduct a retrospective study on these possible factors (including demographics, comorbid diseases, and medications) for their association, if any, with severity of histopathologic findings. This study hypothesize that certain risk factors, specifically those contributing to or consisting of metabolic syndrome, will have higher NASH Fibrosis stages.

Conditions

  • Non-Alcoholic Fatty Liver Disease
  • Non Alcoholic Steatohepatitis

Interventions

OTHER

NAFLD/NASH

the characteristics of patients with advanced fibrosis in a community-based referral center.

Sponsors & Collaborators

  • Methodist Health System

    lead OTHER

Principal Investigators

  • Mantry Parvez, MD · The Liver Institute at Methodist Dallas Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-24
Primary Completion
2021-04-07
Completion
2021-04-07

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05357352 on ClinicalTrials.gov